Opinion
Video
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
Video content above is prompted by the following:
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.